Neutropenia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Neutropenia. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Neutropenia receives a directional strategic score of 56/100, combining unmet need (65/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (83/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

A decrease in the number of NEUTROPHILS found in the blood.

The reproducible entity is Patsnap disease ID c7879aa9883f473695aea6cc7470cb48 with MeSH identifier D009503. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Epidemiology of Sjögren’s: A Systematic Literature Review Epidemiology of Sjo¨gren’s: A Systematic LiteratureReview

100,000 persons [21–23, 26]. The range of inci- dence estimates identified in this SLR exceeded the range found in Qin et al. 2015 (6.9–20.1 per 100,000 person-years) [11], with the prevalence estimates identified in both studies proving to be even more variable. The current SLR identi- fied a prevalence range of 12.4–13.1 per 100,000 person-years or 22.0–770.0 per 100,000 persons (once metrics were scaled to 100,000 persons) [27, 34]. Qin et al. 2015 observed even larger variability in prevalence estimates, ranging from 11.3–3790.1 per 100,000 persons [11]. This wide variation affirms the need for robust, population-wide epidemiology studies to fur- ther understand the incidence and prevalence of Sjo¨gren’s.

Review the epidemiology source

Epidemiology evidence 2: Epidemiology of Neuralgic Amyotrophy—A RetrospectiveAnalysis of Data From a Large German HealthInsurance Company Epidemiology of Neuralgic Amyotrophy—A Retrospective Analysis of Data From a Large German Health Insurance Company

On average, the first diagnosis of NA was made in 2620 in- sured persons per year, corresponding to an incidence of 10.3/100,000 (Table 1). A more frequent diagnosis was made during the first quarter than during the second, third and fourth quarters (on average, 723 versus 632 cases, corre- sponding to an extrapolated annual incidence of 11.3 versus 9.9/100,000, as shown in Table 2 and Figure 1). This discrep- ancy was highly statistically significant (p < 0.001). Overall, there was a steady, significant decline in the incidence of NA from 12.8 in 2013 to 7.7/100,000 in 2022 over the time period analyzed (OR per year 0.948; 95% CI [0.944;0.952]; p < 0.001) (Figure 2). The prevalence of NA in the overall population averaged 20.8/100,000 from 2013 to 2022. As shown for the incidence of NA, we also report a significant decline from 21.2 in 2013 to 19.7/100,000 in 2022 (OR per year 0.991; 95% CI [0.988; 0.994]; p < 0.001). The highest prevalence was seen in the 50–59 y age group at 33.4/100,000, and the lowest in the ≤ 19 y age group at 2.1/100,000 (Figure 3). A ratio of 1:1.2 men to women was observed in all age groups. The distribution of NA prevalence within Germany is heterogeneous (Figure 4). TABLE 1 | Incidence and prevalence during the study period. TABLE 2 | Incidence by annual quarter. FIGURE 1 | Incidence by annual quarter. The incidence of NA is sig- nificantly higher in the first quarter than in quarters two through four. ***p < 0.001. While the overall rate is lower in the eastern federal states (17.4 vs. 24.3/100,000), a distinct north–south divide emerges in the

Review the epidemiology source

Epidemiology evidence 3: Global report on neglected tropical diseases 2025 2.1 Progress against road map indicators 2021–2030

• Under the independence scenario, the prevalence rate declined from 0.355 in 1990 to 0.137 in 2021, resulting in a corresponding drop in the number of affected individuals from nearly 1.9 billion to just over 1.0 billion. The average prevalence rate was 0.238, with 1.51 billion people affected per year. • The maximal scenario yielded the lowest average prevalence rate of 0.137, with 866 million individuals affected annually; the prevalence rate and the number of people affected decreased from 0.217 and 1.158 billion in 1990 to 0.075 and 595 million in 2021. Whichever scenario is used, the trend is consistent and underscores substantial progress in reducing disease burden over the past three decades, even amid population growth. Taken together, the scenario-based estimates for 2021 and the long-term trend data reinforce the importance of interpreting NTD prevalence as a range, rather than as a single fixed figure. This allows for better reflection of real-world complexities such as co-endemicity, programmatic scale-up and socioeconomic disparities in disease exposure. NTD prevalence: projections and limitations Based on historical trends from 1990 to 2021 and projections using the independence coinfection scenario, the number of individuals affected by at least one NTD is expected to continue declining until 2030 (Fig. 2.13). In 2022, the estimated number of affected individuals was approximately 1.06 billion (95% confidence interval [CI]: 1.04–1.08 billion). By 2030, this number is projected to decrease to 860 million (95% CI: 693–1.03 billion), representing a reduction of

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Neutropenia, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Neutropenia thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: IL-1β

Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744). Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908).

The mechanism anchor is IL1B. It is a pathway hypothesis, not a claim that every Neutropenia patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 830 registered studies. Recent sampled records include:

• NCT07763054 — Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients; Recruiting; Not Applicable; sponsor not stated; enrollment 30.
• CTR20263048 — 注射用两性霉素B脂质体生物等效性试验; 进行中 （尚未招募）; Not Applicable; sponsor Changzhou Wuhe Biomedical Co., Ltd.; enrollment Target enrollment: 国内: 98  Enrolled: 国内: 登记人暂未填写该信息 Actual enrollment: 国内: 登记人暂未填写该信息.
• NCT07724756 — Phase II Study of QLC2519 in Pediatric Solid Tumor Participants; Recruiting; Phase 2; sponsor Qilu Pharmaceutical Co., Ltd.; enrollment 18.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

The search returned 1 recent directly matched transaction records:

• Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma (2025-02-12). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate IL1B relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Neutropenia merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if IL1B modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Neutropenia is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.